☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

Minnesota | 41-1597886 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
1001 Third Avenue South | ||||
Minneapolis, | Minnesota | 55404 | ||
(Address of principal executive offices) | (Zip Code) | |||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.01 per share | SNBR | Nasdaq Global Select Market |
Large accelerated filer | ☐ | Accelerated filer | ☒ | |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |
Emerging growth company | ☐ |
i | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Page | ||
1 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
June 28, 2025 | December 28, 2024 | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $1,349 | $1,950 | |
Accounts receivable, net of allowances of $1,127 and $1,113, respectively | 16,017 | 17,516 | |
Inventories | 99,450 | 103,152 | |
Prepaid expenses | 20,824 | 14,568 | |
Other current assets | 37,885 | 44,098 | |
Total current assets | 175,525 | 181,284 | |
Non-current assets: | |||
Property and equipment, net | 109,105 | 129,574 | |
Operating lease right-of-use assets | 339,149 | 356,641 | |
Goodwill and intangible assets, net | 66,301 | 66,412 | |
Deferred income taxes | 31,803 | 33,575 | |
Other non-current assets | 82,629 | 93,324 | |
Total assets | $804,512 | $860,810 | |
Liabilities and Shareholders’ Deficit | |||
Current liabilities: | |||
Borrowings under revolving credit facility | $563,900 | $546,600 | |
Accounts payable | 111,212 | 107,619 | |
Customer prepayments | 41,141 | 46,933 | |
Accrued sales returns | 15,650 | 19,092 | |
Compensation and benefits | 20,929 | 31,038 | |
Taxes and withholding | 17,854 | 18,619 | |
Operating lease liabilities | 82,209 | 82,307 | |
Other current liabilities | 50,326 | 55,804 | |
Total current liabilities | 903,221 | 908,012 | |
Non-current liabilities: | |||
Operating lease liabilities | 287,585 | 307,201 | |
Other non-current liabilities | 94,394 | 97,183 | |
Total liabilities | 1,285,200 | 1,312,396 | |
Shareholders’ deficit: | |||
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding | — | — | |
Common stock, $0.01 par value; 142,500 shares authorized, 22,771 and 22,388 shares issued and outstanding, respectively | 228 | 224 | |
Additional paid-in capital | 31,942 | 27,390 | |
Accumulated deficit | (512,858) | (479,200) | |
Total shareholders’ deficit | (480,688) | (451,586) | |
Total liabilities and shareholders’ deficit | $804,512 | $860,810 |
2 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Net sales | $327,925 | $408,413 | $721,186 | $878,862 | |||
Cost of sales | 134,180 | 166,923 | 286,906 | 361,198 | |||
Gross profit | 193,745 | 241,490 | 434,280 | 517,664 | |||
Operating expenses: | |||||||
Sales and marketing | 146,464 | 182,400 | 335,567 | 390,912 | |||
General and administrative | 29,604 | 39,573 | 68,223 | 78,652 | |||
Research and development | 9,420 | 11,578 | 20,323 | 24,019 | |||
Restructuring costs | 8,332 | 1,819 | 8,392 | 12,419 | |||
Total operating expenses | 193,820 | 235,370 | 432,505 | 506,002 | |||
Operating (loss) income | (75) | 6,120 | 1,775 | 11,662 | |||
Interest expense, net | 11,734 | 12,270 | 22,815 | 24,569 | |||
Loss before income taxes | (11,809) | (6,150) | (21,040) | (12,907) | |||
Income tax expense (benefit) | 13,203 | (1,099) | 12,618 | (374) | |||
Net loss | $(25,012) | $(5,051) | $(33,658) | $(12,533) | |||
Basic net loss per share: | |||||||
Net loss per share – basic | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||
Weighted-average shares – basic | 22,903 | 22,614 | 22,804 | 22,560 | |||
Diluted net loss per share: | |||||||
Net loss per share – diluted | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||
Weighted-average shares – diluted | 22,903 | 22,614 | 22,804 | 22,560 | |||
3 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total | ||||||
Shares | Amount | ||||||||
Balance at December 28, 2024 | 22,388 | $224 | $27,390 | $(479,200) | $(451,586) | ||||
Net loss | — | — | — | (8,646) | (8,646) | ||||
Stock-based compensation | 346 | 3 | 3,948 | — | 3,951 | ||||
Repurchases of common stock | (74) | — | (563) | — | (563) | ||||
Balance at March 29, 2025 | 22,660 | $227 | $30,775 | $(487,846) | $(456,844) | ||||
Net loss | — | — | — | (25,012) | (25,012) | ||||
Stock-based compensation | 149 | 1 | 1,548 | — | 1,549 | ||||
Repurchases of common stock | (38) | — | (381) | — | (381) | ||||
Balance at June 28, 2025 | 22,771 | $228 | $31,942 | $(512,858) | $(480,688) | ||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total | ||||||
Shares | Amount | ||||||||
Balance at December 30, 2023 | 22,235 | $222 | $16,716 | $(458,866) | $(441,928) | ||||
Net loss | — | — | — | (7,482) | (7,482) | ||||
Stock-based compensation | 134 | 1 | 4,116 | — | 4,117 | ||||
Repurchases of common stock | (43) | — | (570) | — | (570) | ||||
Balance at March 30, 2024 | 22,326 | $223 | $20,262 | $(466,348) | $(445,863) | ||||
Net loss | — | — | — | (5,051) | (5,051) | ||||
Stock-based compensation | 32 | 1 | 3,991 | — | 3,992 | ||||
Repurchases of common stock | (3) | — | (42) | — | (42) | ||||
Balance at June 29, 2024 | 22,355 | $224 | $24,211 | $(471,399) | $(446,964) | ||||
4 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Six Months Ended | |||
June 28, 2025 | June 29, 2024 | ||
Cash flows from operating activities: | |||
Net loss | $(33,658) | $(12,533) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||
Depreciation and amortization | 29,096 | 34,177 | |
Stock-based compensation | 5,500 | 8,109 | |
Net loss on disposals and impairments of assets | 775 | 2,500 | |
Deferred income taxes | 1,772 | (5,144) | |
Changes in operating assets and liabilities: | |||
Accounts receivable | 1,499 | 6,587 | |
Inventories | 3,702 | 19,588 | |
Income taxes | 2,470 | 774 | |
Prepaid expenses and other assets | 10,381 | (1,483) | |
Accounts payable | 8,354 | (18,464) | |
Customer prepayments | (5,792) | (4,625) | |
Accrued compensation and benefits | (10,086) | 7,153 | |
Other taxes and withholding | (3,235) | (1,345) | |
Other accruals and liabilities | (9,582) | (11,776) | |
Net cash provided by operating activities | 1,196 | 23,518 | |
Cash flows from investing activities: | |||
Purchases of property and equipment | (8,052) | (14,075) | |
Payment to secure contractual rights | (3,280) | — | |
Issuance of note receivable | — | (2,942) | |
Net cash used in investing activities | (11,332) | (17,017) | |
Cash flows from financing activities: | |||
Net increase (decrease) in short-term borrowings | 12,356 | (6,408) | |
Repurchases of common stock | (944) | (612) | |
Debt issuance costs | (1,877) | — | |
Net cash provided by (used in) financing activities | 9,535 | (7,020) | |
Net decrease in cash and cash equivalents | (601) | (519) | |
Cash and cash equivalents, at beginning of period | 1,950 | 2,539 | |
Cash and cash equivalents, at end of period | $1,349 | $2,020 | |
5 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
6 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
June 28, 2025 | December 28, 2024 | ||
Raw materials | $6,415 | $11,434 | |
Work in progress | 168 | 130 | |
Finished goods | 92,867 | 91,588 | |
$99,450 | $103,152 |
2025 (excluding the six months ended June 28, 2025 ) | $117 | |
2026 | 222 | |
2027 | 222 | |
2028 | 155 | |
2029 | 99 | |
2030 | 45 | |
Total future amortization for definite-lived intangible assets | $860 |
7 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
June 28, 2025 | December 28, 2024 | ||
Outstanding borrowings | $563,900 | $546,600 | |
Outstanding letters of credit | $6,847 | $7,147 | |
Additional borrowing capacity | $101,753 | $123,753 | |
Weighted-average interest rate | 7.9% | 7.6% |
8 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Operating lease costs(1) | $26,649 | $26,909 | $53,186 | $53,735 | |||
Variable lease costs(2) | $37 | $8 | $140 | $(41) | |||
2025 (excluding the six months ended June 28, 2025) | $52,797 |
2026 | 99,002 |
2027 | 82,575 |
2028 | 69,001 |
2029 | 48,062 |
2030 | 34,064 |
Thereafter | 51,219 |
Total operating lease payments(2) | 436,720 |
Less: Interest | 66,926 |
Present value of operating lease liabilities | $369,794 |
June 28, 2025 | December 28, 2024 | |||
Weighted-average remaining lease term (in years) | 5.2 | 5.4 | ||
Weighted-average discount rate | 6.7% | 6.6% |
9 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Six Months Ended | ||||
(in thousands) | June 28, 2025 | June 29, 2024 | ||
Cash paid for amounts included in present value of operating lease liabilities | $53,092 | $54,300 | ||
Right-of-use assets obtained in exchange for operating lease liabilities | $12,752 | $16,313 | ||
June 28, 2025 | December 28, 2024 | ||
Deferred contract assets included in: | |||
Other current assets | $28,793 | $30,154 | |
Other non-current assets | 45,996 | 48,988 | |
$74,789 | $79,142 |
June 28, 2025 | December 28, 2024 | ||
Deferred contract liabilities included in: | |||
Other current liabilities | $37,008 | $38,129 | |
Other non-current liabilities | 58,362 | 60,988 | |
$95,370 | $99,117 |
10 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Retail stores | $287,974 | $358,584 | $632,415 | $773,339 | |||
Online, phone, chat and other | 39,951 | 49,829 | 88,771 | 105,523 | |||
Total Company | $327,925 | $408,413 | $721,186 | $878,862 | |||
Six Months Ended | |||
June 28, 2025 | June 29, 2024 | ||
Balance at beginning of year | $19,092 | $22,402 | |
Additions that reduce net sales | 36,098 | 46,664 | |
Deductions from reserves | (39,540) | (48,535) | |
Balance at end of period | $15,650 | $20,531 | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Stock awards (1) | $1,064 | $3,294 | $1,503 | $6,438 | |||
Stock options | 485 | 698 | 3,997 | 1,671 | |||
Total stock-based compensation expense (1) | $1,549 | $3,992 | $5,500 | $8,109 | |||
11 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Net loss | $(25,012) | $(5,051) | $(33,658) | $(12,533) | |||
Reconciliation of weighted-average shares outstanding: | |||||||
Basic weighted-average shares outstanding | 22,903 | 22,614 | 22,804 | 22,560 | |||
Dilutive effect of stock-based awards | — | — | — | — | |||
Diluted weighted-average shares outstanding | 22,903 | 22,614 | 22,804 | 22,560 | |||
Net loss per share – basic | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||
Net loss per share – diluted | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Cash restructuring costs: | |||||||
Contract termination costs (1) | $1,409 | $(230) | $1,295 | $4,183 | |||
Severance and employee-related benefits | 6,335 | 401 | 6,492 | 1,242 | |||
Professional fees and other | — | 1,648 | 17 | 4,494 | |||
Total cash restructuring costs | 7,744 | 1,819 | 7,804 | 9,919 | |||
Non-cash restructuring costs: | |||||||
Asset impairments (2) | 588 | — | 588 | 2,500 | |||
Total restructuring costs | $8,332 | $1,819 | $8,392 | $12,419 | |||
12 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
June 28, 2025 | December 28, 2024 | ||
Balance at the beginning of year | $3,341 | $8,720 | |
Expenses | 7,804 | 14,888 | |
Cash payments | (7,973) | (20,267) | |
Balance at the end of the period | $3,172 | $3,341 |
Cumulative | ||
June 28, 2025 | ||
Cash restructuring costs: | ||
Contract termination costs (1) | $15,732 | |
Severance and employee-related benefits | 14,685 | |
Professional fees and other | 5,761 | |
Total cash restructuring costs | 36,178 | |
Non-cash restructuring costs: | ||
Asset impairments (2) | 6,008 | |
Total restructuring costs | $42,186 |
13 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Net Sales | $327,925 | $408,413 | $721,186 | $878,862 | |||
Less: | |||||||
Cost of sales | (134,180) | (166,923) | (286,906) | (361,198) | |||
Marketing expenses | (62,427) | (89,483) | (160,368) | (198,512) | |||
Selling expenses | (84,037) | (92,917) | (175,199) | (192,400) | |||
General and administrative | (29,604) | (39,573) | (68,223) | (78,652) | |||
Research and development | (9,420) | (11,578) | (20,323) | (24,019) | |||
Restructuring costs | (8,332) | (1,819) | (8,392) | (12,419) | |||
Interest expense | (11,734) | (12,270) | (22,815) | (24,569) | |||
Income tax (expense) benefit | (13,203) | 1,099 | (12,618) | 374 | |||
Net loss | $(25,012) | $(5,051) | $(33,658) | $(12,533) | |||
14 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Six Months Ended | |||
June 28, 2025 | June 29, 2024 | ||
Balance at beginning of period | $6,947 | $8,503 | |
Additions charged to costs and expenses for current-year sales | 5,878 | 7,675 | |
Deductions from reserves | (5,800) | (8,048) | |
Changes in liability for pre-existing warranties during the current year, including expirations | (983) | (171) | |
Balance at end of period | $6,042 | $7,959 | |
15 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
16 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
17 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
18 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
19 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||||||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||||||||||
Net sales | $327.9 | 100.0% | $408.4 | 100.0% | $721.2 | 100.0% | $878.9 | 100.0% | |||||||
Cost of sales | 134.2 | 40.9% | 166.9 | 40.9% | 286.9 | 39.8% | 361.2 | 41.1% | |||||||
Gross profit | 193.7 | 59.1% | 241.5 | 59.1% | 434.3 | 60.2% | 517.7 | 58.9% | |||||||
Operating expenses: | |||||||||||||||
Sales and marketing | 146.5 | 44.7% | 182.4 | 44.7% | 335.6 | 46.5% | 390.9 | 44.5% | |||||||
General and administrative | 29.6 | 9.0% | 39.6 | 9.7% | 68.2 | 9.5% | 78.7 | 8.9% | |||||||
Research and development | 9.4 | 2.9% | 11.6 | 2.8% | 20.3 | 2.8% | 24.0 | 2.7% | |||||||
Restructuring costs | 8.3 | 2.5% | 1.8 | 0.4% | 8.4 | 1.2% | 12.4 | 1.4% | |||||||
Total operating expenses | 193.8 | 59.1% | 235.4 | 57.6% | 432.5 | 60.0% | 506.0 | 57.6% | |||||||
Operating (loss) income | (0.1) | —% | 6.1 | 1.5% | 1.8 | 0.2% | 11.7 | 1.3% | |||||||
Interest expense, net | 11.7 | 3.6% | 12.3 | 3.0% | 22.8 | 3.2% | 24.6 | 2.8% | |||||||
Loss before income taxes | (11.8) | (3.6%) | (6.2) | (1.5%) | (21.0) | (2.9%) | (12.9) | (1.5%) | |||||||
Income tax expense (benefit) | 13.2 | 4.0% | (1.1) | (0.3%) | 12.6 | 1.7% | (0.4) | 0.0% | |||||||
Net loss | $(25.0) | (7.6%) | $(5.1) | (1.2%) | $(33.7) | (4.7%) | $(12.5) | (1.4%) | |||||||
Net loss per share: | |||||||||||||||
Basic | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||||||||||
Diluted | $(1.09) | $(0.22) | $(1.48) | $(0.56) | |||||||||||
Weighted-average number of common shares: | |||||||||||||||
Basic | 22.9 | 22.6 | 22.8 | 22.6 | |||||||||||
Diluted | 22.9 | 22.6 | 22.8 | 22.6 | |||||||||||
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Retail stores | 87.8% | 87.8% | 87.7% | 88.0% | |||
Online, phone, chat and other | 12.2% | 12.2% | 12.3% | 12.0% | |||
Total Company | 100.0% | 100.0% | 100.0% | 100.0% | |||
20 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Sales change rates: | |||||||
Retail comparable-store sales (1) | (18%) | (11%) | (17%) | (10%) | |||
Online, phone and chat | (19%) | (13%) | (16%) | (16%) | |||
Total Retail comparable sales change (1) | (19%) | (11%) | (17%) | (11%) | |||
Net opened/closed stores and other | (1%) | 0% | (1%) | 0% | |||
Total Company | (20%) | (11%) | (18%) | (11%) | |||
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Average sales per store (1) (in thousands) | $2,395 | $2,732 | |||||
Average sales per square foot (1) | $775 | $883 | |||||
Stores > $2 million in net sales (2) | 47% | 62% | |||||
Stores > $3 million in net sales (2) | 13% | 21% | |||||
Average revenue per smart bed unit – Total Retail (3) | $5,880 | $5,802 | $5,940 | $5,782 | |||
Three Months Ended | Six Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Beginning of period | 637 | 661 | 640 | 672 | |||
Opened | 1 | 4 | 3 | 10 | |||
Closed | (8) | (19) | (13) | (36) | |||
End of period | 630 | 646 | 630 | 646 | |||
21 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
22 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
23 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
24 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Six Months Ended | |||
June 28, 2025 | June 29, 2024 | ||
Total cash provided by (used in) : | |||
Operating activities | $1.2 | $23.5 | |
Investing activities | (11.3) | (17.0) | |
Financing activities | 9.5 | (7.0) | |
Net decrease in cash and cash equivalents | $(0.6) | $(0.5) | |
25 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Trailing-Twelve Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Net loss | $(25,012) | $(5,051) | $(41,459) | $(40,039) | |||
Income tax expense (benefit) | 13,203 | (1,099) | 7,830 | (10,730) | |||
Interest expense | 11,734 | 12,270 | 46,614 | 48,214 | |||
Depreciation and amortization | 13,697 | 16,347 | 59,590 | 69,676 | |||
Stock-based compensation | 1,549 | 3,992 | 8,835 | 13,073 | |||
Restructuring costs (1) | 8,332 | 1,819 | 14,039 | 28,147 | |||
CEO transition/Proxy contest costs (2) | 53 | — | 2,825 | — | |||
Asset impairments | — | — | 1,220 | 490 | |||
Adjusted EBITDA | $23,556 | $28,278 | $99,494 | $108,831 | |||
Six Months Ended | Trailing-Twelve Months Ended | ||||||
June 28, 2025 | June 29, 2024 | June 28, 2025 | June 29, 2024 | ||||
Net cash provided by (used in) operating activities | $1,196 | $23,518 | $(9,228) | $(4,230) | |||
Subtract: Purchases of property and equipment | 8,052 | 14,075 | 18,796 | 41,232 | |||
Free cash flow | $(6,856) | $9,443 | $(28,024) | $(45,462) | |||
26 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Trailing-Twelve Months Ended | |||
June 28, 2025 | June 29, 2024 | ||
Adjusted net operating profit after taxes (Adjusted NOPAT) | |||
Operating income | $12,983 | $(2,555) | |
Add: Operating lease expense (1) | 25,535 | 27,750 | |
Less: Income taxes (2) | 1,500 | (6,104) | |
Adjusted NOPAT | $40,018 | $19,091 | |
Average adjusted invested capital | |||
Total deficit | $(480,688) | $(446,964) | |
Add: Long-term debt (3) | 564,101 | 540,480 | |
Add: Operating lease obligations (4) | 369,794 | 408,724 | |
Total adjusted invested capital at end of period | $453,207 | $502,240 | |
Average adjusted invested capital (5) | $477,676 | $509,369 | |
Adjusted return on invested capital (Adjusted ROIC) (6) | 8.4% | 3.7% | |
27 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
28 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Period | Total Number of Shares Purchased(1)(2) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3) | ||||
March 29, 2025 through April 26, 2025 | 4,459 | $5.03 | — | $348,071,000 | ||||
April 27, 2025 through May 24, 2025 | 426 | $8.87 | — | $348,071,000 | ||||
May 25, 2025 through June 28, 2025 | 33,573 | $10.57 | — | $348,071,000 | ||||
Total | 38,458 | $9.91 | — | $348,071,000 |
29 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
30 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Exhibit Number | Description | |
10.1* | ||
10.2† | ||
10.3† | ||
31.1* | ||
31.2* | ||
32.1* | ||
32.2* | ||
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
31 | 2Q 2025 FORM 10-Q | SLEEP NUMBER CORPORATION | |
SLEEP NUMBER CORPORATION | |||
(Registrant) | |||
Dated: | July 31, 2025 | By: | /s/ Linda Findley |
Linda Findley | |||
Chief Executive Officer | |||
(principal executive officer) | |||
By: | /s/ Kelly F. Baker | ||
Kelly F. Baker | |||
Interim Principal Accounting Officer | |||
(principal accounting officer) | |||